About Shanghai Haohai Biological Technology Company

The company is a scientific and technological innovation enterprise that uses biomedical materials technology and genetic engineering technology for R&D, production and sales of medical devices and pharmaceuticals. It is committed to providing innovative medical products to the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, gradually realizing import substitution of related pharmaceutical products, and becoming a leading enterprise in the field of biomedical materials. The company was listed on the main board of the Hong Kong Stock Exchange and the Science and Technology Innovation Board of the Shanghai Stock Exchange on April 30, 2015 and October 30, 2019 respectively, becoming the first “Hong Kong Stock + Science and Technology Innovation Board” biomedical listed company in the country. The Group is a technology-innovative enterprise engaged in R&D, production and sales of medical devices and pharmaceuticals. It is committed to providing innovative medical products to the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, gradually realizing import substitution of related pharmaceutical products, and becoming a leading enterprise in the field of biomedical materials. Main products: intraocular lenses, ophthalmic viscoelastic agents, corneal shaping lenses, PRL, hyaluronic acid, orthopedic joint cavity viscoelastic supplements, anti-adhesion and hemostasis, etc. The company has received honors such as the National Science and Technology Progress Award and the second prize of the National Science and Technology Progress Award.